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pNaKtide Attenuates 
Steatohepatitis and Atherosclerosis 
by Blocking Na/K-ATPase/ROS 
Amplification in C57Bl6 and ApoE 
Knockout Mice Fed a Western Diet
Komal Sodhi1, Krithika Srikanthan1, Perrine Goguet-Rubio1, Alexandra Nichols1, Amrita 
Mallick1, Athar Nawab1, Rebecca Martin1, Preeya T. Shah1, Muhammad Chaudhry  1, Saroj 
Sigdel1, Mehiar El-Hamdani  1, Jiang Liu1, Zijian Xie1, Nader G. Abraham1,2 & Joseph I. 
Shapiro1
We have previously reported that the α1 subunit of sodium potassium adenosine triphosphatase 
(Na/K-ATPase), acts as a receptor and an amplifier for reactive oxygen species, in addition to its distinct 
pumping function. On this background, we speculated that blockade of Na/K-ATPase-induced ROS 
amplification with a specific peptide, pNaKtide, might attenuate the development of steatohepatitis. 
To test this hypothesis, pNaKtide was administered to a murine model of NASH: the C57Bl6 mouse 
fed a “western” diet containing high amounts of fat and fructose. The administration of pNaKtide 
reduced obesity as well as hepatic steatosis, inflammation and fibrosis. Of interest, we also noted 
marked improvement in mitochondrial fatty acid oxidation, insulin sensitivity, dyslipidemia and 
aortic streaking in this mouse model. To further elucidate the effects of pNaKtide on atherosclerosis, 
similar studies were performed in ApoE knockout mice also exposed to the western diet. In these mice, 
pNaKtide not only improved steatohepatitis, dyslipidemia, and insulin sensitivity, but also ameliorated 
significant aortic atherosclerosis. Collectively, this study demonstrates that the Na/K-ATPase/ROS 
amplification loop contributes significantly to the development and progression of steatohepatitis 
and atherosclerosis. And furthermore, this study presents a potential treatment, the pNaKtide, for the 
metabolic syndrome phenotype.
Metabolic syndrome represents a cluster of metabolic abnormalities including obesity, hypertension, dyslipi-
demia, and insulin resistance with obesity and insulin resistance recognized as the causative factors1–3. Together, 
these derangements present a significant risk for nonalcoholic steatohepatitis, atherosclerosis, and diabetes, all 
of which lead to cardiovascular complications. Cardiovascular disease is still the leading cause of mortality in 
Western countries, with approximately 30% of deaths in the United States attributed to it refs 2 and 4.
Recent studies have demonstrated that oxidative stress and inflammation underlie the pathogenesis of met-
abolic syndrome and, by extension, NASH and atherosclerosis5–7. Redox imbalance, accompanied by insulin 
resistance, dyslipidemia and increased circulating FFA levels, are features that usually accompany clinical NASH6. 
Additionally, deficient hepatic mitochondrial fatty acid oxidation contributes to triglyceride accumulation and 
steatosis8. It is believed that NASH predisposes to atherosclerosis through the systemic release of inflammatory 
and oxidative-stress mediators9. Atherosclerosis, itself, is caused by oxidative stress, as oxidized lipids appear to 
play a pathogenic role10, 11.
We have previously noted that Na/K-ATPase signaling can serve as a feed-forward amplifier for oxidant sign-
aling12–15. Our group has developed a cell permeant NaKtide (pNaKtide) from the N domain of the α1 subunit of 
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Na/K-ATPase. This peptide inhibits Na/K-ATPase-ROS amplification and blocks downstream Src activation16–19. 
We have recently shown that pNaKtide, by restoring redox balance in adipocytes, attenuates obesity in mice fed 
a high fat diet20. Given the aforementioned importance of oxidative stress in the pathophysiology of NASH, we 
chose to examine whether pNaKtide might be effective in ameliorating NASH in C57Bl6 mice fed a western diet. 
As the effects of pNaKtide detailed in this report extended to the vascular system, additional studies were per-
formed in the ApoE knockout mouse.
Results
Effect of pNaKtide on body weight, visceral and subcutaneous fat content and liver weight in 
mice fed a western diet. C57Bl6 mice were fed a western diet for 4 weeks and then administered pNaKtide 
at a dose of 25 mg/kg intraperitoneal (I.P.) every week while the western diet was continued for an additional 8 
weeks. The administration of pNaKtide reduced body weight, visceral fat, and subcutaneous content in these mice 
significantly (Table 1) as we have previously reported20. Further, our results demonstrated that liver weight, which 
is indicative of fatty liver, was also significantly reduced by pNaKtide administration (Table 1). In parallel experi-
ments, rhodamine-labeled peptide accumulated in hepatic tissue (Supplementary Fig. 1A). Previous studies doc-
umented that ApoE−/− mice are relatively resistant to weight gain until fed a western diet for approximately 6 
months21. In line with these reports, our results showed that body weight, visceral fat, subcutaneous fat, and liver 
weight were not significantly increased in ApoE−/− mice fed a western diet as compared to mice on a standard 
chow diet (Table 1).
Effect of pNaKtide on energy expenditure and locomotor activity in mice fed a western 
diet. Energy expenditure, determined as heat production (kcal/kg/hour), was significantly decreased in both 
strains of mice fed a western diet compared to mice fed a normal chow diet (Table 1). The administration of pNa-
Ktide significantly increased energy expenditure suggesting that these groups utilized more calories compared to 
mice fed a western diet (Table 1). Also oxygen consumption was increased in both C57Bl6 and ApoE−/− mice 
fed a western diet and treated with pNaKtide (Table 1). Similarly, treatment with pNaKtide significantly increased 
locomotor activity, as determined by the ambulatory count over a 24-hour period (Table 1).
Effect of pNaKtide on fatty acid oxidation genes in adipose tissue of mice fed a western 
diet. Since adipose mitochondria participate in energy expenditure through fatty acid oxidation, quantitative 
PCR was done to measure fatty acid oxidation genes in adipose tissue. Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α) is a major regulator of mitochondrial oxidative metabolism22. Our results 
showed that PGC-1α mRNA expression was significantly decreased in adipose tissue of C57Bl6 or ApoE−/− 
mice fed a western diet compared to the control group (Table 2). Administration of pNaKtide significantly 
increased PGC-1α mRNA expression in these mice. Carnitinepalmitoyltransferase-1 (CPT-1) is a rate-limiting 
enzyme of mitochondrial fatty acid β-oxidation23. CPT-1 mRNA expression was decreased in both C57Bl6 and 
ApoE−/− mice fed a western diet compared to control mice and this decrease was reversed by treatment with 
pNaKtide (Table 2). The UCP 1 and 2 are markers of energy metabolism and its uncoupled energy is used for 
heat production in fat tissue24. Our results demonstrated that both strains of mice fed a western diet exhibited 
decreased expression of UCP 1 and 2 in adipose tissue in comparison to mice fed a normal diet. Our results 
showed that UCP1 and 2 mRNA expressions were significantly increased by pNaKtide treatment in adipose tissue 
compared to mice fed a western diet in both strains of mice (Table 2).
Effect of pNaKtide on hepatic lipogenesis and inflammation in mice fed a western 
diet. Histological sections of liver tissue from C57Bl6 mice fed a western diet showed significant inflammation 
C57Bl6 ApoE−/−
CTR WD WD + pNaKtide CTR WD WD + pNaKtide
BW (g, Baseline) 22.5 ± 0.7 21.4 ± 0.4 20.1 ± 0.7 20.6 ± 0.4 20.7 ± 0.6 21.2 ± 0.6
BW (g, 4 week) 24.7 ± 1.08 25.6 ± 0.7 24.9 ± 0.9 24.4 ± 0.6 25.8 ± 0.7 26.9 ± 1.04
BW (g, 12 week) 28.2 ± 1.1 40.7 ± 0.8** 32.9 ± 0.9**,## 28.5 ± 1.04 29.9 ± 1.06 30.4 ± 1.5
Visceral fat (g) 0.5 ± 0.05 3.1 ± 0.1** 1.9 ± 0.1**,## 0.5 ± 0.02 0.5 ± 0.06 0.5 ± 0.02
SC Fat (g) 0.4 ± 0.03 1.9 ± 0.1** 0.9 ± 0.06**,## 0.3 ± 0.02 0.3 ± 0.02 0.3 ± 0.02













3083.01 ± 72.1 2622.05 ± 138.5* 3155 ± 129.06# 3799.7 ± 75.3 3342.2 ± 93.9* 3704.5 ± 82.5#
Table 1. Effect of pNaKtide on body weight; visceral fat, subcutaneous fat and liver weight; energy expenditure; 
locomotor activity and oxygen consumption in C57Bl/6 and ApoE−/− mice fed a western diet. Results are 
means ± SEM, n = 6/group. *p < 0.05, **p < 0.01 vs. control; #<0.05, ##p < 0.01 vs WD.
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and a large number of vacuoles in the liver. C57Bl6 mice treated with pNaKtide exhibited decreased lipid and 
inflammatory cell infiltration as seen by H&E staining (Fig. 1A).
H&E staining of liver tissues from ApoE−/− mice fed a western diet also had a significant increase in lipid and 
inflammatory cell infiltration compared to control ApoE−/− mice. pNaKtide decreased lipid and inflammatory 
cell infiltration compared to mice fed a western diet (Fig. 1B). Both C57Bl6 and ApoE−/− mice fed a western diet 
had significantly increased lipid accumulation in the liver compared to mice fed a normal chow diet (Fig. 1C,D) 
as demonstrated by Oil red O staining and administration of pNaKtide decreased this. Increased fat accumulation 
in hepatocytes is mostly attributed to enhanced uptake and synthesis of fatty acids and triglycerides25. Our results 
showed that hepatic triglycerides and FFA levels were significantly increased in C57Bl6 and ApoE−/− mice fed a 
western diet compared to control mice (Table 3). As expected, pNaKtide treatment significantly decreased hepatic 
triglycerides and FFA levels compared to mice fed a western diet.
Fatty acid synthase (FAS) expression, an important marker of lipogenesis, was increased in both strains of 
mice fed a western diet and this elevated level was decreased to control levels with pNaKtide treatment (Table 3). 
CD36, a fatty acid transport protein, contributes to the progression of inflammation in NASH5, 26. Our results 
showed that CD36 mRNA expression was significantly increased in both strains of mice fed a western diet com-
pared to control mice, and this increase was negated by treatment with pNaKtide (Table 3). Similarly, F4/80, 
MCP-1 and IL-6 mRNA expression, markers of macrophage/kupffer cell infiltration and inflammation27, were 
also increased in both strains of mice fed a western diet compared to control mice (Table 3). These changes were 
significantly attenuated with pNaKtide treatment.
Effect of pNaKtide on hepatic fibrosis in mice fed a western diet. Masson’s trichrome staining of 
liver sections from both strains of mice fed a western diet demonstrated focal portal fibrosis (blue staining) com-
pared to control mice and this increase was negated by treatment with pNaKtide (Fig. S3A,B). Excess collagen 
synthesis in the liver is a sensitive indicator of NASH and fibrosis28. Type 1-collagen levels were significantly 
increased in both strains of mice fed a western diet, and this was significantly decreased to control levels with 
pNaKtide treatment (Fig. S3C,D). Similarly, mRNA expression of hepatic fibronectin, MMP9 and MMP13, genes 
related to fibrogenesis29, 30, were also elevated in both strains of mice fed a western diet, and these increases were 
also attenuated with pNaKtide treatment (Table 3).
Effect of pNaKtide on hepatic p-Src, ERK, and α1 carbonylation in mice fed a western 
diet. Protein carbonyl groups are widely used markers for oxidative stress15. We have shown previously that 
reactive oxygen species (ROS) initiates carbonylation of the α1 Na/K-ATPase subunit which in turn activates the 
Src signaling cascade with downstream modulation of extracellular signal-regulated kinase 1/2 (ERK1/2)20. Our 
results showed that carbonylation of the α1 Na/K-ATPase subunit was increased in C57Bl6 and ApoE−/− mice 
fed a western diet, and this increase was negated by pNaKtide treatment (Fig. 2A and B). Treatment with pNaK-
tide also blocked Na/K-ATPase-regulated Src and ERK 1/2 activation in both strains of mice fed a western diet 
(Fig. 2C–F). Further our results showed that TBARS, another marker of oxidative stress, was decreased by pNa-
Ktide treatment compared to mice fed a western diet (Table 3), demonstrating pNaKtide-mediated abrogation of 
NASH and oxidative stress.
Effect of pNaKtide on hepatic mitochondrial fatty acid oxidation in mice fed a western 
diet. Mitochondria play an important role in energy metabolism, being the primary site for fatty acid oxida-
tion in the liver31–33. Our results showed that hepatic PGC1α levels were decreased in both strains of mice fed 
a western diet compared to the control groups, and pNaKtide treatment significantly increased hepatic PCG1α 
expression (Fig. 3A and B). In the mitochondrial extract of both mice strains fed a western diet, the hepatic 
expression of CPT-1 was less compared to the control group (Fig. 3C and D). Administration of pNaKtide 
increased CPT-1 levels significantly compared to mice fed a western diet. Long-chain acyl-CoA dehydrogenase 
(LCAD), is involved in the first reaction of mitochondrial fatty acid oxidation and is important for energy home-
ostasis23. Similar to previous studies34, 35, our results demonstrated that LCAD levels were significantly increased 
by pNaKtide treatment in liver mitochondrial extracts compared to mice fed a western diet (Fig. 3E and F). 
Quantitative PCR was also done for the above genes and our results followed the same trend as the Western blot 
analysis. As expected, PCG1α, CPT-1 and LCAD mRNA expression were significantly increased by pNaKtide 
treatment in both C57Bl6 and ApoE−/− mice fed a western diet (Table 3).
Effect of pNaKtide on metabolic profile in mice fed a western diet. The insulin resistance phe-
notype in both strains of mice fed a western diet was reversed by the administration of pNaKtide. This was 
C57Bl6 ApoE−/−
CTR WD WD + pNaKtide CTR WD WD + pNaKtide
PGC1α mRNA 0.9 ± 0.003 0.5 ± 0.02* 1.9 ± 0.03*,## 0.9 ± 0.003 0.4 ± 0.06** 1.4 ± 0.1*,##
CPT1 mRNA 0.9 ± 0.003 0.3 ± 0.03* 1.3 ± 0.2## 0.9 ± 0.003 0.4 ± 0.06* 1.9 ± 0.3*,##
UCP1 mRNA 0.9 ± 0.03 0.1 ± 0.01* 1.3 ± 0.1## 0.9 ± 0.003 0.3 ± 0.04* 2.2 ± 0.6#
UCP2 mRNA 0.9 ± 0.003 0.2 ± 0.05* 2.1 ± 0.3**,## 0.9 ± 0.003 0.2 ± 0.04* 1.3 ± 0.3##
Table 2. Effect of pNaKtide on adipose tissue fat oxidation genes in C57Bl6 and ApoE−/− mice fed a western 
diet. Relative mRNA expression of adipose tissue genes. Results are means ± SEM, n = 8/group. *p < 0.05, 
**p < 0.01 vs. control; #<0.05, ##p < 0.01 vs WD.
www.nature.com/scientificreports/
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Figure 1. Effect of pNaKtide on liver histology and hepatic lipid accumulation and steatohepatitis in C57Bl6 
(Panel A) and APOE−/− (Panel B) fed a western diet (defined in methods). Representative H&E staining in 
liver in C57Bl6 (A) and ApoE−/− (B) mice, representative Oil Red O slides in C57Bl6 (C) and ApoE−/− 
(D) mice and quantification of Oil Red O stain shown in bottom. Quantification displayed as mean ± SEM, 
n = 8–10/group, *p < 0.05 vs control, #p < 0.05 vs WD, **p < 0.01 vs control, ##p < 0.01 vs WD.
C57Bl6 ApoE−/−
CTR WD WD + pNaKtide CTR WD WD + pNaKtide
Lipid Accumulation Markers
Liver triglycerides (mg 
TG/mg protein) 0.1 ± 0.01 0.4 ± 0.04** 0.2 ± 0.01
## 0.8 ± 0.03 2.05 ± 0.1** 0.9 ± 0.08##
Liver FFA (nmol/100 mg) 18.3 ± 1.2 30.4 ± 2.5** 17.3 ± 0.8*,## 7.5 ± 1.06 27.4 ± 4.7** 11.09 ± 1.8#
FAS mRNA 0.9 ± 0.003 3.2 ± 0.1** 1.4 ± 0.3## 0.9 ± 0.003 2.8 ± 0.5** 1.3 ± 0.1##
CD36 mRNA 0.9 ± 0.003 4.1 ± 0.3** 1.9 ± 0.5## 0.9 ± 0.003 2.6 ± 0.1** 1.1 ± 0.1##
Fatty Acid Oxidation Markers
PGC1α mRNA 1.01 ± 0.02 0.5 ± 0.09* 1.2 ± 0.01## 1.01 ± 0.02 0.6 ± 0.03** 1.1 ± 0.02##
CPT1 mRNA 1.01 ± 0.02 0.6 ± 0.03* 1.4 ± 0.1## 1.01 ± 0.02 0.4 ± 0.1* 1.3 ± 0.08##
LCAD mRNA 1.006 ± 0.02 0.4 ± 0.03** 1.7 ± 0.2*,## 1.006 ± 0.02 0.4 ± 0.07* 1.2 ± 0.07##
Oxidative Stress Markers
TBARS (umol/mg 
protein) 19.4 ± 1.04 31.2 ± 1.3** 18.1 ± 2.8
## 21.6 ± 3.5 48.5 ± 7.1** 28.1 ± 1.4#
Inflammatory Markers
F4/80 mRNA 0.9 ± 0.003 3.1 ± 0.3** 1.3 ± 0.1## 0.9 ± 0.003 2.1 ± 0.2** 1.3 ± 0.1##
MCP-1 mRNA 0.9 ± 0.003 2.4 ± 0.2** 1.3 ± 0.1## 0.9 ± 0.003 3.9 ± 0.2** 2.2 ± 0.5##
IL-6 mRNA 0.9 ± 0.003 3.5 ± 0.8** 1.2 ± 0.1# 0.9 ± 0.003 3.5 ± 0.8* 1.2 ± 0.1#
Fibrosis Markers
Fibronectin mRNA 0.9 ± 0.003 2.4 ± 0.2** 0.5 ± 0.04## 0.9 ± 0.003 2.5 ± 0.3** 0.9 ± 0.06##
MMP-13 mRNA 0.9 ± 0.003 2.8 ± 0.1** 1.08 ± 0.1## 0.9 ± 0.003 3.3 ± 0.7* 2.3 ± 0.9
MMP-9 mRNA 0.9 ± 0.004 3.5 ± 0.1** 1.02 ± 0.1## 0.9 ± 0.004 2.08 ± 0.3** 1.2 ± 0.2##
Table 3. Effect of pNaKtide on hepatic lipid accumulation markers, inflammatory, fibrotic markers, and 
mitochondrial fatty acid oxidation genes in C57Bl/6 and ApoE−/− mice fed a western diet. Results are 
means ± SEM, n = 6–8/group. *p < 0.05, **p < 0.01 vs. control; #<0.05, ##p < 0.01 vs WD.
www.nature.com/scientificreports/
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characterized by improved glucose tolerance (Fig. 4) and a significant improvement in the homeostasis model 
assessment of insulin resistance (HOMA-IR) score (Table 4). Increased plasma ALT, FFA and triglycerides levels 
are strongly associated with insulin resistance and NASH. The administration of pNaKtide significantly atten-
uated the diet induced increase in plasma ALT, triglyceride, and FFA levels in C57Bl6 and ApoE−/− mice fed 
a western diet (Table 4). Treatment of pNaKtide also significantly decreased plasma LDL levels in C57Bl6 and 
ApoE−/− mice fed a western diet (Table 4). Further, our results showed that both strains of mice fed a western 
diet had decreased plasma HDL levels (Table 4) and this decrease was reversed by pNaKtide. Generation of ROS 
has been implicated in the pathogenesis of NASH and atherosclerosis. Our results showed that administration of 
pNaKtide decreased plasma ROS levels in both strains of mice fed a western diet (Table 4).
Figure 2. Effect of pNaKtide on α1 carbonylation and Na/K-ATPase/Src/ROS amplification signaling pathway 
in livers of C57Bl6 and ApoE−/− mice. Whole cell lysates were prepared with Nonidet P-40 buffer and Western 
blot analysis was performed to determine protein carbonylation with Ponceau S staining as a loading control in 
C57Bl6 (A) and ApoE−/− (B) mice, activation of c-Src in C57Bl6 (C) and ApoE−/− (D) and activation of ERK 
1/2 in C57Bl658 and ApoE−/− (F) with mean band density normalized to total Src and total ERK respectively. 
Results are expressed as means ± SE, n = 6–8/group, **p < 0.01 vs control, ##p < 0.01 vs WD.
www.nature.com/scientificreports/
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Effect of pNaKtide on aorta architecture and plaques in mice fed a western diet. Bright field 
images of whole and open aortas were taken and Sudan IV staining of open aortas was performed in C57Bl6 
and as expected, there was no gross evidence of atherosclerotic plaques (data not shown). Cross-sections of the 
C57Bl6 aortas were stained with Oil Red O to estimate lipid deposition. Lipid accumulation in the aorta was 
increased in mice fed a western diet compared to the control group (Fig. S4). Treatment with pNaKtide signifi-
cantly decreased lipid staining compared to mice fed a western diet.
Figure 3. Effect of pNaKtide on hepatic mitochondrial fatty acid oxidation in C57Bl6 and ApoE−/− mice 
fed a western diet. PGC1α Western blot analysis of liver homogenates, with data shown as mean band density 
normalized to actin in C57Bl6 (A) and ApoE−/− (B) mice, CPT-1 Western blot analysis of mitochondrial 
isolates from liver homogenates, with data shown as mean band density normalized to porin in C57Bl6 (C) 
and ApoE−/− (D) mice, and LCAD Western blot analysis of mitochondrial isolates from liver homogenates, 
with data shown as mean band density normalized to porin in C57Bl6 (E) and ApoE−/− (F) mice. Results are 
means ± SE, n = 6/group, *p < 0.05 vs control, #p < 0.05 vs. WD, **p < 0.01 vs control, ##p < 0.01 vs WD.
www.nature.com/scientificreports/
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The purpose of using the ApoE−/− mouse was to examine the atherosclerosis process. Bright field images of 
dissected aortas were taken to visualize and quantify lesion size in ApoE−/− mice. In both the whole closed aorta 
and open aorta images (Fig. 5A and B respectively), ApoE−/− mice fed a western diet had increased plaque size. 
This was significantly decreased by pNaKtide treatment. These data were confirmed with Sudan IV staining for 
lipid deposition (Fig. 6A). The Sudan IV staining was significantly decreased in pNaKtide treated ApoE−/− mice, 
which demonstrated decreased lipid deposition. Experiments with rhodamine-labeled pNaKtide did not demon-
strate pNaKtide localization to aortic plaques (Supplementary Fig. 1B). Oil Red O staining of the aorta demon-
strated increased lipid accumulation in ApoE−/− mice fed a western diet compared to the control group, and 
treatment with pNaKtide significantly decreased this lipid deposition (Fig. 6B). Furthermore, H&E staining of 
the aorta revealed a significant increase in cross-sectional lesion area with intimal thickening, acellular matrix of 
lipid pool, mixed inflammatory cell infiltrate, and necrotic area in ApoE−/− mice fed a western diet (Fig. 6C). All 
of these outcomes- lesion size, necrotic core area, inflammatory cell infiltration, and intimal thickness improved 
with pNaKtide treatment (Fig. 6C).
Discussion
This study demonstrates that Na/K-ATPase amplification of oxidant signaling is important in the pathophysiol-
ogy of NASH and atherosclerosis in the murine models studied. We report that the metabolic syndrome pheno-
type, present in both C57Bl6 and ApoE−/− mice fed a western diet, improved with pNaKtide treatment which 
attenuated Na/K-ATPase induced oxidant amplification20. Obesity, as measured by body weight and visceral fat 
weight, was significantly reduced in C57Bl6 mice but not in ApoE−/− mice treated with the pNaKtide. We sug-
gest that this is a consequence of the ApoE−/− mouse being relatively resistant to weight gain with the western 
diet21. In order to determine the mechanism by which pNaKtide affected adiposity, we utilized the CLAMS sys-
tem to measure metabolic rate. We observed that both energy expenditure and activity level were significantly 
increased in pNaKtide treatment groups compared to animals fed a western diet, suggesting that increased energy 
expenditure is at least partly responsible for reduced adiposity in mice fed a western diet. Adipose mitochondria 
regulate whole-body energy metabolism via dissipating energy and generating heat in adipose tissue8. PGC1α 
and CPT-1 are essential for adipose tissue fatty acid oxidation8, 22, 36. UCP-1 and 2 play important roles in the 
control of energy expenditure by uncoupling respiration from ATP synthesis, thereby dissipating energy as heat 
and affecting energy metabolism efficiency37, 38. In our study, we have shown that C57BL6 and ApoE−/− mice 
Figure 4. Effect of pNaKtide on glucose tolerance test (GTT) in C47Bl6 (A) and ApoE−/− (B) mice fed a 
western diet. Data displayed as mean ± SEM, n = 8–10/group, *p < 0.05 vs control, #p < 0.05 vs WD, **p < 0.01 
vs control, ##p < 0.01 vs WD.
C57Bl6 ApoE−/−
CTR WD WD + pNaKtide CTR WD WD + pNaKtide
HOMA-IR 0.8 ± 0.08 2.5 ± 0.3** 1.09 ± 0.03## 1.3 ± 0.06 5.6 ± 0.4** 2.1 ± 0.1##
ALT (U/L) 3.5 ± 0.9 7.9 ± 0.6** 4.9 ± 0.4# 3.3 ± 0.6 6.9 ± 0.8** 4.2 ± 0.5#
Triglycerides (mg/dl) 24.3 ± 1.7 39.8 ± 4.8** 26.8 ± 1.6# 94.02 ± 4.2 147.6 ± 3.1** 116 ± 9.05##
FFA (mmol/l) 0.2 ± 0.02 0.9 ± 0.07** 0.6 ± 0.06*,# 0.4 ± 0.04 1.03 ± 0.08** 0.6 ± 0.08#
LDL (mg/dl) 10.2 ± 0.7 42.6 ± 3.1** 23.5 ± 3.1**,## 101.4 ± 4.9 239.5 ± 16.2** 158.3 ± 7.3**,##
HDL (mg/dl) 48.4 ± 0.7 14.5 ± 1.03** 45.7 ± 2.9## 32.9 ± 2.01 8.1 ± 2.6** 28.3 ± 3.2##
ROS (mmol) 1.01 ± 0.1 4.6 ± 0.7** 1.5 ± 0.3## 1.4 ± 0.4 6.6 ± 0.06** 3.3 ± 0.6##
Table 4. Effect of pNaKtide on metabolic profile in plasma of C57Bl6 and ApoE−/− mice fed a western diet. 
Results are means ± SEM, n = 6/group. *p < 0.05, **p < 0.01 vs. control; #<0.05, ##p < 0.01 vs WD.
www.nature.com/scientificreports/
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fed a WD have decreased CPT-1, UCP-1, UCP-2, and PGC1α mRNA expression levels in adipose tissue. This was 
significantly improved with pNaKtide treatment. Increased CPT-1 and PGC1α expression with pNaKtide may be 
related to an increase in fatty acid oxidation8. Given the established relationship between UCP-1 and 2 and ther-
mogenesis, pNaKtide may increase metabolic rate and energy metabolism in adipose tissue20. Overall, we suggest 
that pNaKtide increases fat utilization by increasing mitochondrial fatty acid oxidation in adipose tissue, oxygen 
consumption, and metabolic rate leading to an overall decrease in both body weight and visceral adiposity.
Since obesity is closely associated with NASH, the effect of pNaKtide on steatohepatitis was evaluated. 
According to the two-hit hypothesis, hepatic steatosis appears to be a prerequisite for subsequent events that lead 
to NASH39. Obesity and insulin resistance result in increased release of FFAs from adipocytes and increased 
hydrolysis of TGs, which contribute to elevated plasma levels of FFA40. Furthermore, increased FFAs induce 
oxidative stress via ROS generation25, which may initiate the Na/K-ATPase/ROS amplification pathway to prop-
agate steatosis and NASH. Treatment with pNaKtide showed significant attenuation of hepatic steatosis as evi-
dent by decreased lipid staining, FAS expression, and TG and FFA concentrations in the livers of C57Bl6 and 
ApoE−/− mice fed a western diet. Also, pNaKtide attenuated CD36 expression, which we have previously linked 
to Na/K-ATPase signaling41. In addition, ALT, a well-established marker of liver injury, was also decreased by 
pNaKtide treatment42.
Oxidative stress and inflammation are known to underlie the etiopathogenesis of NASH43, 44 and can be cat-
egorized as the second hit with regard to the two hit hypothesis. pNaKtide decreased hepatic α1 carbonylation, 
p-Src, and downstream p-ERK expression to attenuate Na/K-ATPase-induced ROS amplification. Mitochondria 
play a central role in ATP production and energy expenditure through fatty acid oxidation31–33. Our results 
showed that pNaKtide treatment increased hepatic expression of genes involved in fatty acid oxidation including 
CPT-1, PGC1α and LCAD in the setting of caloric excess, to ameliorate the NASH phenotype. Collectively, it 
appears that pNaKtide, through its mitigation of ROS, has a favorable effect on mitochondrial biogenesis and 
fatty acid oxidation in the setting of a WD. It promotes increased substrate utilization, decreased lipid storage, 
and most importantly minimizes the impact ROS has on these processes, therefore limiting the impact of a second 
hit.Consequences of oxidative stress (ROS) include lipid peroxidation, which can cause direct damage to hepat-
ocytes and induce an inflammatory response with upregulation of inflammatory cytokines such as MCP-1 and 
IL-645. We have shown TBARS (a marker of oxidative stress), MCP-1 and IL-6 are all decreased with pNaKtide. 
Further, our results show that administration of pNaKtide significantly attenuated WD-induced inflammatory 
cell infiltration in hepatic tissue. This close interaction of ROS and inflammatory cytokines may be how pNaK-
tide (via the Na/K-ATPase signaling cascade) is able to mitigate the inflammatory component of the second hit, 
necessary for the development of NASH. With regard to fibrosis, prior studies have shown that the Na/K-ATPase 
Figure 5. Effect of pNaKtide on atherosclerotic plaque size in ApoE−/− mice aortas fed a western diet. Bright 
field images of whole closed aortas (A) and open aortas (B) in ApoE−/− mice fed a western diet. The amount 
of lesion formation in each animal was expressed as a ratio of plaque integral density to total surface area of the 
aorta. Results are shown as means ± SEM, n = 8/group, **p < 0.01 vs control, ##p < 0.01 vs. WD.
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signal cascade, once initiated, activates PKCδ through ROS amplification. PKCδ then phosphorylates Fli-1, which 
in turn, increases collagen expression16–19. We have similarly shown an increase in hepatic collagen expression 
in WD fed mice, and pNaKtide significantly decreased collagen deposition. Overall, there was significant atten-
uation of NASH in C57Bl6 and ApoE−/− mice fed a WD by pNaKtide, as evidenced by decreased lipid accu-
mulation, inflammatory cell infiltration, and trichrome staining for fibrosis. This is supported by findings of 
decreased markers of lipogenesis (FAS, liver TG/FFAs, CD36), inflammation (IL-6, MCP-1, F4/80), and fibrosis 
(fibronectin, MMP9, MMP13, collagen-1). We propose that pNaKtide treatment, by decreasing ROS through the 
Na/K-ATPase pathway, was sufficient to suppress the oxidative stress and inflammation necessary to attenuate 
steatohepatitis.
NASH is associated with insulin resistance (IR), which results in hypertriglyceridemia and hyperglycemia, 
which in turn, increases plasma FFAs in the circulation. Increased levels of FFAs in plasma induce oxidative 
stress via ROS generation46. Dyslipidemia is frequently observed in patients with NASH, and treatment of dys-
lipidemia plays a critical role in the overall management of these patients. pNaKtide improved insulin sensitivity 
and dyslipidemia, which prompted an examination of how pNaKtide affected vascular disease. Increased levels 
of circulating FFAs and oxidative stress lead to increased lipid deposition within the vasculature, atherosclerosis, 
and ultimately cardiovascular complications46. Elevated LDL levels have been associated with an increase in the 
amount of cholesterol entering the plaque47, 48. More importantly, an increase in serum HDL may contribute to 
active LDL removal from the vessel wall and from macrophage or foam cells49. In the C57Bl6 mouse fed a western 
diet, fatty streaking was markedly reduced by pNaKtide. We further saw attenuation of aortic atherosclerosis in 
the ApoE−/− mouse fed a western diet. We suggest that pNaKtide’s beneficial effect on atherosclerosis was sec-
ondary to a favorable systemic lipid profile. The pNaKtide significantly reduced plasma LDL and TG levels and 
increased HDL50. Whether the plaque decrease observed in this study will translate into significant reductions in 
clinical events is yet to be determined, however modifying the levels of harmful and protective lipids should still 
be an important clinical objective. Taken together, this study demonstrates that pNaKtide improves the metabolic 
syndrome phenotype, specifically obesity, NASH, insulin resistance, dyslipidemia, and atherosclerosis, effects that 
are mediated by blockage of the Na/K-ATPase/ROS amplification loop. Unfortunately, we were only able to study 
male animals in the current study. Certainly, the effects of gender and female sex hormones on the development 
of oxidant stress and obesity may be extremely important.
At this juncture, we would offer a disclaimer that there are a number of interventions that have been shown 
to be effective in improving the perturbations associated with obesity in these animal models, and some of these 
Figure 6. Effect of pNaKtide on atherosclerotic plaque size in ApoE−/− mice aortas fed a western diet. Sudan 
IV staining for lipid deposition in open aortas (A), oil red O staining for lipid accumulation in aorta cross-
sectional images (B), and aorta H&E staining (C). Quantified results shown as mean ± SEM, n = 8/group, 
*p < 0.05 vs control, **p < 0.01 vs control, ##p < 0.01 vs. WD.
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have even been found to be effective in clinical practice. However, we would argue that our approach focusing on 
Na/K-ATPase induced oxidant amplification is novel and potentially presents a new and effective target for thera-
peutic intervention in the treatment of obesity and its related manifestation dyslipidemia, NASH and atheroscle-
rosis. It should not be forgotten that obesity, metabolic syndrome, diabetes and cardiovascular disease present an 
increasing burden on healthcare systems and cost in the world today. The approach outlined in this report offers 
a portal to decreasing the increasing burden that obesity places on society.
In conclusion, we noted that oxidant stress characterized the metabolic syndrome, NASH and vascular 
abnormalities induced by a western diet in both C57Bl6 and ApoE−/− mice. We further noted that addressing 
Na/K-ATPase signaling associated oxidant amplification with pNaKtide ameliorated these abnormalities. Should 
these data be confirmed in humans, strategies like pNaKtide, which focus on this oxidant amplification loop, may 
potentially augment our clinical approach to these problems.
Material and Methods
Experimental Design. All animal studies were approved by the Marshall University Animal Care and 
Use Committee in accordance with the National Institutes of Health Guidelines for Care and Use of Laboratory 
Animals. C57Bl6 mice and ApoE knockout mice (6–8 weeks old, male) were purchased from Jackson Laboratory. 
Upon arrival to the Byrd Biotechnology Center, ARF, Animal Research Facility, mice were placed in cages and 
were fed normal chow diet and had access to water ad libitum or were fed Western Diet (WD) and had ad libitum 
access to high fructose solution. Western diet containing fructose is a well-known model of diet induced meta-
bolic syndrome, and it contributes to chronic metabolic imbalance and to the development of NASH and ather-
osclerosis51–53. WD was purchased commercially from Envigo (Indianapolis, IN). WD contained 42% fat, 42.7% 
carbohydrate, and 15.2% protein yielding 4.5 KJ/g. Fructose was purchased commercially from Alfa Aesar (Ward 
Hill, MA). Fructose was made at a concentration of 42 g/L, yielding 0.168 KJ/mL. The animals were randomly 
divided into 4 groups (8–10 mice per group) as follows: (1) Control, (2) Control + pNaKtide, (3) WD, and (4) 
WD + pNaKtide. The number of animals in each group was determined by power analysis following assumptions 
derived from our previous study with mice54, using a variance of 0.2 within the groups, power of 0.80, and alpha 
error of 0.05. After 4 weeks of control or WD diet respectively, group 2 and group 4 were injected with pNaKtide 
for 8 weeks (dissolved in saline and injected I.P. at a dose of 25-mg/kg-body weight every 7 days. The body weight 
was measured every week. At the end of the 12-week period, mice were placed on an 8-hour fast, anesthetized 
with sodium pentobarbital (65 mg/kg, I.P.) and blood was obtained from the tail vein for measurement of glu-
cose using a glucometer and measurement of insulin using ELISA assay kit (Abcam, Cambridge, MA). At the 
time of sacrifice, body weight, visceral fat content, and liver weight of all mice were measured. Liver tissue and 
aortas were flash frozen in liquid nitrogen and maintained at −80 °C until assayed. Blood samples were collected 
for lipid profile measurement. Our results showed that there was no significant difference between the Control 
and Control + pNaKtide C57Bl6 group with regard to body weight (Supplementary Fig. S2A), glucose tolerance 
(Supplementary Fig. S2B), triglycerides (Supplementary Fig. S2C), HDL (Supplementary Fig. S2D), and LDL 
(Supplementary Fig. S2E). Therefore we proceeded without the Control + pNaKtide group in subsequent C57BL6 
and ApoE knockout mouse studies.
Indirect calorimetry and locomotor activity. At the end of the 12-week experimental period, energy 
expenditure and locomotor activity were measured using an eight-chamber CLAM (Columbus Instruments, 
Columbus, OH, USA). In this system, total oxygen consumption (VO2) and carbon dioxide production (VCO2) 
were measured, and VO2 was converted to individual heat production (kcal/hour) by Columbus software. This 
software calculates the heat production by multiplying the calorific value CV = 3.815 + (1.232 × RER) by the 
observed VO2 (Heat = CV × VO2). The energy expenditure is then calculated as a ratio of heat produced divided 
by body mass. A system of infrared beams detects movement of animals in CLAMS, and locomotor activity was 
determined as ambulatory count, the number of times different beams were broken in either the x- or y-axes 
during an interval. All mice were acclimatized to monitoring cages for 24 hours prior to an additional 48 hours of 
recordings under the regular 12-hour light–dark cycle.
Blood measurement of LDL, HDL, Triglycerides and Free Fatty Acids (FFA). Plasma LDL and 
HDL levels were determined using an ELISA Assay according to manufacturer protocols (Abcam, Cambridge, 
MA). Triglycerides and FFA levels were quantified using a Quantification Assay Kit according to manufacturer 
protocols (Abcam, Cambridge, MA).
Blood ROS and hepatic TBARS measurement. Plasma ROS levels were determined using the 
OxiSelectTM In Vitro ROS Assay Kit according to manufacturer’s protocols (Cell Biolabs, Inc, San Diego, CA). 
Hepatic oxidative injury was measured as TBARS using an assay kit according to manufacturer’s protocol 
(Cayman Chemical, Ann Arbor, MI). Liver samples were homogenized in a buffer solution containing 50 mM 
tris-HCL (pH 7.4) and 1.15% KCL and then centrifuged. The supernatant was used for the assay. Data were nor-
malized to total protein and presented as micromoles per milligram of protein.
Glucose tolerance test. Glucose clearance was determined using an intraperitoneal glucose tolerance test 
before termination of the experiment. Mice were fasted for 8 h, after which a glucose solution (2 g/kg body weight, 
injected as a 10% solution) was injected into the peritoneal cavity. Samples were taken from the tail vein at 0, 30, 
60, 90, and 120 min after glucose injection. Blood glucose was measured using the Accutrend Sensor glucometer.
Determination of homeostasis model assessment of insulin resistance. The HOMA-IR was cal-
culated from mouse blood using glucose and insulin concentrations obtained after 8 hours of food withdrawal, 
using the following formula:
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− = × . .HOMA IR [fasting insulin (ng/mL) fasting glucose (mM)]/22 5
Distribution of rhodamine B labeled pNaKtide. Mice were injected (by i.p.) without (as control) or 
with rhodamine B labeled pNaKtide (25 mg/Kg body weight). Three hours after injection, the mice were sacrificed 
and the hepatic tissues were imaged and analyzed. The images were taken at laser power 5% (emission readings 
for rhodamine B are 580–650 nm) with a Leica SP5 TCS II equipped with coherent chameleon multiphoton vision 
II (IR) laser and analyzed by Leica LAS/AF software.
Determination of Triglyceride and FFA levels in hepatic tissue. For triglyceride measurement, liver 
samples were homogenized in ice-cold phosphate-buffered saline (PBS). Tissue lipids were extracted with meth-
anol/chloroform (1:2), dried, and resuspended in 5% fat-free bovine serum albumin. Triglyceride levels were 
determined using a commercially available kit according to the manufacture’s protocol (Abcam, Cambridge, 
MA). For FFA measurement, liver tissue was homogenized in 1% (w/v) Triton X-100 in chloroform solution. 
After centrifugation of samples, the lower organic phase was collected and dried to remove chloroform. The dried 
lipids were dissolved in fatty acid assay buffer and FFA levels were determined using a commercially available kit 
according to the manufacturer’s protocol (Sigma-Aldrich, St. Louis, MO).
Histopathological examination in hepatic tissue. Liver samples from each group were fixed in 4% par-
aformaldehyde, dehydrated, embedded in paraffin, and sectioned. Formalin-fixed, paraffin-embedded sections 
were cut (6 μm thick) and mounted on glass slides. The sections were deparaffinized in xylene and hematoxylin 
and eosin and Masson’s trichrome staining were performed for histological analysis.
Oil Red-O staining. For Oil Red O staining, liver and aorta tissues, which were frozen in OCT compounds, 
were cut into 6 μm sections, mounted on slides and allowed to dry for 1–2 hours. The sections were fixed with 
4% paraformaldehyde (PFA) for 1 hour and then the slides were rinsed with PBS (pH 7.4). After air-drying, the 
slides were stained in 0.3% Oil Red O solution for 3 minutes. The slides were rinsed with distilled water 2 times 
and mounted with 87% glycerol. The microphotographs were taken on a Nikon Eclipse 80i microscope equipped 
with a Nikon camera head DS-Fi1 (Nikon, Japan). For quantitative analysis, the total area of red pixels on the 
Oil-Red-O stained tissue section was measured by using the Image J software provided by NIH. The data were 
expressed as the mean ± SEM of percentage of the Oil-Red-O stained areas with respect to total area.
Aorta Dissection and Sudan IV staining. Aorta Harvesting. The aorta was dissected and harvested 
under a stereomicroscope from the iliac bifurcation to the aortic root, including the brachiocephalic trunk, left 
common carotid artery, and left subclavian artery. The adventitial fat was removed. The aortic trunk was washed 
with cold PBS and pinned onto a black wax surface.
Whole Aorta Imaging. Bright field images of the dissected aorta were taken with a Leica stereomicroscope (Leica 
MZ10F; Leica Microsystems, Buffalo Grove, IL) attached to a QImaging Camera (Q26644; Surrey, Canada) at a 
total magnification of 8x (objective lens was 0.8x and eye piece lens was 10x).
Open Aorta Imaging. Whole aortas were opened longitudinally from the aortic root to the iliac bifurcation and 
pinned to a black wax surface. Bright field mages were acquired using a Leica stereomicroscope attached to a 
QImaging Camera at a total magnification of 8x.
Sudan IV Staining. To identify lipid rich intraluminal lesions, the aortas were stained with commercially avail-
able Sudan IV (Sigma, St Louis, MO). A 0.5% Sudan IV solution was made using acetone and ethanol at an equal 
ratio. Tissues were treated with 70% ethanol for 5 minutes followed by Sudan IV for 15 minutes. They were then 
washed with 80% ethanol for 3 minutes and rinsed with PBS for 3 minutes. Finally tissues were treated with 0.4% 
PFA for storage and imaging.
Haematoxylin and Eosin Staining. The aorta, stored in OCT, was cut into 6 μm sections and stained with haema-
toxylin and eosin for histological analysis.
Quantification of Aortic Lesions. Quantification of atherosclerotic lesions was done using Image J 1.49 V (NIH). 
The amount of lesion formation in each animal was expressed as a ratio of plaque integral density to total surface 
area of the aorta.
Measurement of c-Src and ERK1/2 phosphorylation. Whole cell lysates from hepatic tissue were prepared with 
NP-40 buffer and activation of c-Src and ERK 1/2 was determined as previously described by Yan et al.15, 55. After 
immunoblotting for phospho-c-Src and phospho- ERK1/2, the same membrane was stripped and immunoblotted 
for total c-Src and total ERK 1/2. Activation of c-Src and ERK1/2 was expressed as the ratios of phospho-c-Src/
total Src and phospho-ERK1/2/total ERK 1/2, respectively with both measurements normalized to 1.0 for the 
control samples.
Assessment of protein carbonylation. Whole-cell lysates from hepatic tissues were prepared with NP-40 buffer 
and western blotting for protein carbonylation assay was done55. The signal density values of control samples were 
normalized to 1.0 with Ponceau S staining as a loading control.
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Western blot analysis. Liver was pulverized with liquid nitrogen and placed in a homogenization buffer. 
Homogenates were centrifuged, the supernatant was isolated, and immunoblotting was performed. The super-
natant was used for the determination of Collagen-1 and PGC1α as previously reported36, 56. Loading condi-
tions were controlled for using tubulin (collagen1) and actin (PGC1α). Mitochondrial extraction was performed 
on hepatic tissue by using a mitochondrial isolation kit (Abcam, Cambridge, MA). In brief, liver tissues were 
minced, and placed in pre-chilled dounce homogenizer. The homogenate was centrifuged at 1000 g for 10 mins 
at 4 degrees and the supernatant was saved. The supernatant was spun at 12000 g for 15 mins at 4 degrees and the 
pellet was saved. The pellet was washed and resuspended in isolation buffer and protease inhibitor, centrifuged at 
12000 g for 15 mins. The pellet was again collected and the process was repeated. The pellet was resuspended in 
isolation buffer and protease inhibitor and used immediately. This mitochondrial homogenate was used for the 
determination of CPT-1 and LCAD and Porin was used as a loading control.
RNA extraction and real-time PCR. Total RNA was extracted from liver and adipose tissue using RNeasy 
Protect Mini kit (QIAGEN, Maryland, USA) according to manufacturer’s instructions. Total RNA (1 μg) was 
transcribed into cDNA using GeneAmp kit (Applied Biosystems, Branchburg, NJ, USA) reverse transcription 
reagents. Total RNA was analyzed by a quantitative real time polymerase chain reaction57. Real-time PCR was 
performed using SYBR Green PCR Master Mix (Applied Biosystems) on a 7500 HT Fast Real-Time PCR System 
(Applied Biosystems). Specific primers used were FAS, CD36, IL-6, F4/80, MCP-1, MMP9, MMP13, fibronectin, 
UCP-1, UCP-2, CPT-1, LCAD, PGC1α and GADPH. Each reaction was performed in triplicate. The comparative 
threshold cycle (Ct) method was used to calculate the fold amplification as specified by the manufacturer. All 
experimental samples were normalized using actin as an internal control and normalization was performed in 
separate reactions.
Statistical analyses. Data were tested for normality and then subjected to parametric analysis. When more than 
two groups were compared, one-way ANOVA was performed prior to comparison of individual groups, and the 
post-hoc t-tests were adjusted for multiple comparisons using the Tukey-Kramer correction. Data are presented 
as mean ± SEM.
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